Lv1
28 积分 2022-10-02 加入
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
1个月前
已完结
Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid
2个月前
已完结
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
2个月前
已完结
Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma
2个月前
已完结
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
2个月前
已完结
New prognostic systems for multiple myeloma in the context of contemporary therapies
2个月前
已完结
What Is Multiple Myeloma?
2个月前
已完结
Bortezomib
3个月前
已完结
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
3个月前
已完结
Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
3个月前
已完结
皖公网安备34019202002308
